BCM
FULC icon

Bridgeway Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Bridgeway Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-95,400
Closed -$878K – 1242
2025
Q3 		$878K Sell
95,400
-2,200
-2% -$15.9K 0.02% 719
2025
Q2 		$671K Hold
97,600
– – 0.02% 719
2025
Q1 		$281K Sell
97,600
-42,400
-30% -$156K 0.01% 850
2024
Q4 		$658K Buy
+140,000
New +$516K 0.01% 763
2024
Q2 		– Sell
-88,564
Closed -$836K – 1297
2024
Q1 		$836K Sell
88,564
-37,936
-30% -$339K 0.02% 789
2023
Q4 		$854K Hold
126,500
– – 0.02% 792
2023
Q3 		$562K Hold
126,500
– – 0.01% 845
2023
Q2 		$417K Buy
+126,500
New +$372K 0.01% 958
2023
Q1 		– Sell
-40,000
Closed -$291K – 1400
2022
Q4 		$291K Sell
40,000
-35,000
-47% -$228K 0.01% 996
2022
Q3 		$607K Buy
+75,000
New +$537K 0.02% 848

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bridgeway Capital Management's FULC Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 95,400 shares — an estimated $878K sold.

Bridgeway Capital Management first reported a position in FULC in Q3 2022 and held it in 10 quarters. The position peaked at $878K in Q3 2025. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

  • Bridgeway Capital Management reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 95,400 Fulcrum Therapeutics shares in Q4 2025, an estimated $878K.
  • Bridgeway Capital Management first reported a position in Fulcrum Therapeutics in Q3 2022 and held it in 10 quarters.
  • Bridgeway Capital Management's Fulcrum Therapeutics position peaked at $878K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.